XML 30 R20.htm IDEA: XBRL DOCUMENT v3.20.1
BIOLOGICAL ASSETS
12 Months Ended
Dec. 31, 2019
BIOLOGICAL ASSETS  
BIOLOGICAL ASSETS

13.BIOLOGICAL ASSETS

The rollforward of biological assets is set forth below:

 

 

 

Balances on December 31, 2017

 

4,548,897

Addition

 

1,285,490

Depletion

 

(709,547)

Loss on fair value adjustment

 

(129,187)

Disposal

 

(47,124)

Other write-offs

 

(12,624)

Balances on December 31, 2018

 

4,935,905

Business combination with Fibria (1)

 

4,579,526

Addition

 

2,849,039

Depletion

 

(1,905,118)

Gain on fair value adjustment

 

185,399

Disposal

 

(23,764)

Other write-offs

 

(49,488)

Balances on December 31, 2019

 

10,571,499


1)

Business combination with Fibria and its subsidiaries held on January 3, 2019, Note 1.2.1.

The calculation of fair value of the biological assets falls under Level 3 in the hierarchy set forth in IFRS 13 — Measurement of Fair Value, due to the complexity and structure of calculation.

The main assumptions, IMA, discount rate, and selling price stand out as being the most sensitive where increases or reductions in these assumptions generate significant gains or losses in the measurement of fair value.

The Company’s biological assets are mainly of eucalyptus forest for reforestation used to supply wood to pulp and paper manufactory facility and are located in the states of São Paulo, Bahia, Espírito Santo, Maranhão, Minas Gerais, Pará, Piauí and Tocantins. Permanent preservation and legal reserve areas were not included in the biological assets fair value measurements due to its nature.

The fair value of eucalyptus forests is determined semiannually through the income approach method by using the discounted cash flow method.

The assumptions used in measurement of the fair value of biological assets were:

i)Average cycle of forest formation of 6 and 7 years;

ii)Effective area of forest from the 3rd year of planting;

iii)Average annual increment consists of the estimated volume of production of wood with bark in m3 per hectare, ascertained based on the genetic material used in each region, silvicultural practices and forest management, production potential, climate factors and ground conditions;

iv)The estimated average standard cost per hectare includes expenses on silvicultural and forest management applied to each year of formation of the biological cycle of forests, plus costs of land lease agreements and opportunity cost of own land;

v)The average gross selling prices of eucalyptus were based on specialized research on transactions carried out by the Company with independent third parties and/or weighted by the cost of formation plus cost of capital plus estimated margin for regions where there is no market benchmark available; and

vi)The discount rate used in cash flows is measured based on capital structure and other economic assumptions in an independent market participant in the sale of standing wood (forests). 

The following table discloses the measurement of the premises adopted:

 

 

 

 

  

December 31,

 

 

2019

Planted useful area (hectare)

 

 988,720

Mature assets

 

 86,352

Immature assets

 

 902,368

Average annual growth (IMA) - m3 /hectare /year

 

 38.34

Average gross sale price of eucalyptus - R$/m3

 

 66.81

Discount rate - %

 

8.4%

 

The pricing model considers net cash flows, after deduction of taxes on profit at the applicable rates.

The fair value adjustment recognized in year ended December 31, 2019 is justified by variation of indicators mentioned above, which combined resulted in a positive variation of R$185,399. The fair value adjustment was recognized under other operating income (expense), net.

 

 

 

 

  

December 31,

 

 

2019

Physical changes

 

(347,409)

Price

 

532,808

 

 

185,399

 

The Company manages the financial risks related to agricultural activities in a preventive manner. To reducing risks from edaphoclimatic factors, the weather is monitored through meteorological stations and, in the event of pests and diseases, our Department of Forestry Research and Development, an area specialized in physiological and phytosanitary aspects, has procedures to diagnose and act rapidly against any occurrences and losses.

The Company has no biological assets pledged in the year ended December 31, 2019.